Genetic
LX101
LX101 is a genetic therapy with 5 clinical trials. Currently 3 active trials ongoing.
Total Trials
5
Max Phase
-
Type
GENETIC
Molecule
-
Success Metrics
Active Trials
3(60%)
Phase Distribution
Ph phase_1
1
20%
Ph phase_1_2
1
20%
Ph phase_2
1
20%
Ph not_applicable
1
20%
Ph phase_3
1
20%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 1/2Combined phases
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Active, not recruiting3
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 1/21 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
N/A1 (20.0%)
Trials by Status
active_not_recruiting360%
not_yet_recruiting240%
Recent Activity
3 active trials
Showing 5 of 5
not_yet_recruitingphase_2
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
NCT07781891
active_not_recruitingphase_1
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06196827
active_not_recruitingphase_3
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632
active_not_recruitingphase_1_2
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
NCT06212297
not_yet_recruitingnot_applicable
An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA
NCT06024057
Clinical Trials (5)
Showing 5 of 5 trials
NCT07781891Phase 2
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
NCT06196827Phase 1
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Phase 3
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06212297Phase 1/2
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
NCT06024057Not Applicable
An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA
All 5 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 5